Benzinga · Aug 13, 2026
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46
JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target from $52 to $46.
OL
NASDAQ · OLMA
Olema Pharmaceuticals, Inc.
Healthcare · Biotechnology
$10.90
Down-$0.21 (-1.93%)
Updated Aug 21, 2026, 11:21 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.17B
- P/E ratio
- -18.05
- Dividend yield
- 0.00%
- 52-week range
- $5.34 – $36.26
- Volume
- 1.04M
- Avg. volume
- 3.41M
Price performance
OLMA price history
1M range · 0 trading sessions · Daily adjusted prices
OLMA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest OLMA news
The latest Smart Investors Daily articles mentioning OLMA.
Stock researchCompany · Overview
OLMA research
Overview
Company profile and research snapshot.
Company profile
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $42.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | JP Morgan | Overweight | — |
| Aug 11, 2026 | Citigroup | Buy | — |
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Guggenheim | Buy | — |
| Mar 27, 2026 | Wolfe Research | Peer Perform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.
Benzinga · Aug 11, 2026
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals shares fall after completing OPERA-01 Phase 3 enrollment, with top-line data now expected in Q1 2027.
Benzinga · Aug 11, 2026
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36
HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $36.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
